3.11.2014
EN
Official Journal of the European Union
C 388/17
Action brought on 2 July 2014 — Novartis Europharm v Commission
(Case T-511/14)
2014/C 388/21
Language of the case: English
Parties
Applicant: Novartis Europharm Ltd (Horsham, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission
Form of order sought
The applicant claims that the Court should:
—
annul the contested decision; and
—
order the European Commission to pay its own costs and those of Novartis.
Pleas in law and main arguments
By its present action, the applicant seeks the annulment of Commission Decision C (2014) 2155 final of 27 March 2014 granting a marketing authorisation to Teva Generics for the medicinal product for human use ‘Zoledronic acid Teva Generics — Zoledronic Acid’.
In support of the action, the applicant relies on a single plea in law, essentially identical or similar to the plea in law relied on in Cases T-472/12 Novartis Europharm v Commission (1) and T-67/13 Novartis Europharm v Commission (2).
(1) OJ 2012 C 389, p. 8.
(2) OJ 2013 C 101, p. 24.
Full & Egal Universal Law Academy